Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma
- Resource Type
- Journal
- Source
CHINESE JOURNAL OF CANCER ; SEP 8 2016, 35 p86 7p.- Subject
- Language
- English
- ISSN
- 1944446X